The ASCO Post Podcast

Latest Episodes:

Five- vs 2-Year Course of Zoledronate for Patients With Early Breast Cancer Jul 09, 2021

Show notes

This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival.

Coverage of stories discussed this week on ascopost.com:

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer

FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates

To listen to more podcasts from ASCO, visit asco.org/podcasts.

News From the EHA 2021 Virtual Congress: Multiple Myeloma, Myelofibrosis, and Leukemia Jul 02, 2021

Show notes

This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

News in Genitourinary Cancers From the 2021 ASCO Annual Meeting Jun 25, 2021

Show notes

This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Lung Cancer Data From the 2021 ASCO Annual Meeting Jun 18, 2021

Show notes

This week, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

2021 ASCO Annual Meeting: Reports on Kidney, Esophageal, and Cervical Cancers Jun 11, 2021

Show notes

This week, we’re continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

100th Episode: Reports From the 2021 ASCO Annual Meeting in Breast, Prostate, and Lung Cancers Jun 04, 2021

Show notes

This week marks our 100th episode of the podcast! We launched at the start of the 2019 ASCO Annual Meeting, and this week, we’re reporting major findings from the 2021 Annual Meeting, including adjuvant therapy for patients with BRCA-mutated breast cancer, LuPSMA for metastatic prostate cancer, and an update on CodeBreak100, the trial that led to the recent FDA approval of sotorasib for KRAS G12C–mutated non–small cell lung cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

USPSTF Recommendation on Colorectal Cancer Screening Beginning at Age 45 May 28, 2021

Show notes

This week, we’re discussing the recent U.S. Preventive Services Task Force, or USPSTF, recommendation on colorectal cancer screening beginning at 45. Then, we’ll hear about a doublet regimen that produced durable responses in patients with advanced head and neck cancer. Lastly, we’ll hear about a study being presented during the ASCO Annual Meeting about a novel immunotherapy combination for advanced melanoma.

Coverage of stories discussed this week on ascopost.com:

USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening

Pembrolizumab Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

2021 ASCO Annual Meeting: Data From a Premeeting Presscast May 21, 2021

Show notes

The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed . On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of Medicaid expansion on long-term survival for patients with cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Comparison of Adjuvant Trastuzumab Courses for Early HER2-Positive Breast Cancer May 14, 2021

Show notes

We’ll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

The COVID-19 Pandemic and Cancer Screening Deficits in the United States

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Dr. John and Liza Marshall on Their New Book Off Our Chests: A Candid Tour Through the World of Cancer May 07, 2021

Show notes

This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor.

The Marshalls are the coauthors of a new book entitled Off Our Chests: A Candid Tour Through the World of Cancer, published this week by IdeaPress Publishing and named one of the “10 Books to Read in May 2021” by The Washington Post.

Together, they discuss the impact of Liza’s breast cancer diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their book has an important message.

To listen to more podcasts from ASCO, visit asco.org/podcasts.